Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said once-daily edoxaban plus heparin met the primary efficacy endpoint of non-inferiority to warfarin plus heparin
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury